Tamjeed Ahmed
Overview
Explore the profile of Tamjeed Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lycan Jr T, Buckenheimer A, Ruiz J, Russell G, Dothard A, Ahmed T, et al.
Am J Hosp Palliat Care
. 2022 May;
40(1):10-17.
PMID: 35512681
Background: Immune checkpoint inhibitors (ICIs) can lead to durable responses in patients with lung cancer but may delay transitions to hospice at the end of life (EOL). We aimed to...
2.
Diaz-Garelli F, Strowd R, Ahmed T, Lycan Jr T, Daley S, Wells B, et al.
JCO Clin Cancer Inform
. 2021 May;
5:527-540.
PMID: 33989015
Purpose: Accurate recording of diagnosis (DX) data in electronic health records (EHRs) is important for clinical practice and learning health care. Previous studies show statistically stable patterns of data entry...
3.
Liu L, Ahmed T, Petty W, Grant S, Ruiz J, Lycan T, et al.
Mol Oncol
. 2020 Oct;
15(2):462-472.
PMID: 33107184
KRAS is a key oncogenic driver in lung adenocarcinoma (LUAD). Chromatin-remodeling gene SMARCA4 is comutated with KRAS in LUAD; however, the impact of SMARCA4 mutations on clinical outcome has not...
4.
Helis C, Hughes R, Glenn C, Lanier C, Masters A, Dohm A, et al.
Int J Radiat Oncol Biol Phys
. 2020 Jul;
108(1):295-303.
PMID: 32615262
Purpose: Immune checkpoint inhibitor (ICI) therapy has recently been found to improve survival in patients with a number of cancers, including those with metastatic disease. There is an association of...
5.
Wu S, Xing F, Sharma S, Wu K, Tyagi A, Liu Y, et al.
J Exp Med
. 2020 Jun;
217(8).
PMID: 32496556
Up to 40% of lung cancer patients develop brain metastasis, and the median survival of these patients remains less than 6 months. Smoking is associated with lung cancer. However, how...
6.
Ahmed T, Lycan T, Dothard A, Ehrlichman P, Ruiz J, Farris M, et al.
Clin Lung Cancer
. 2020 Feb;
21(4):e286-e293.
PMID: 32089478
Introduction: Immunotherapy has become a key treatment for patients with advanced non-small-cell lung cancer (NSCLC). While a survival advantage has been proven for patients who are medically fit, it is...
7.
Diaz-Garelli J, Strowd R, Ahmed T, Wells B, Merrill R, Laurini J, et al.
JAMIA Open
. 2020 Jan;
2(3):369-377.
PMID: 31984369
Background: Structured diagnosis (DX) are crucial for secondary use of electronic health record (EHR) data. However, they are often suboptimally recorded. Our previous work showed initial evidence of variable DX...
8.
Soike M, Logue J, Qasem S, Hughes R, McTyre E, Su J, et al.
Sci Rep
. 2019 Oct;
9(1):14385.
PMID: 31591443
We sought to identify candidate biomarkers for early brain metastasis (BM) recurrence in patients who underwent craniotomy followed by adjuvant stereotactic radiosurgery. RNA sequencing was performed on eight resected brain...
9.
Lanier C, Hughes R, Ahmed T, LeCompte M, Masters A, Petty W, et al.
Neurooncol Pract
. 2019 Sep;
6(5):402-409.
PMID: 31555455
Background: The effect of immunotherapy on brain metastasis patients remains incompletely understood. Our goal was to evaluate its effect on survival, neurologic death, and patterns of failure after stereotactic radiosurgery...
10.
Farris M, Wheless W, Hughes R, Soike M, Masters A, Helis C, et al.
Pract Radiat Oncol
. 2019 Jul;
9(6):e599-e607.
PMID: 31271904
Purpose: Prophylactic cranial irradiation (PCI) reduces the incidence of brain metastases in patients with limited stage small cell lung cancer (LS-SCLC). However, PCI is associated with neurotoxicity. Previous studies have...